Travere Therapeutics, Inc. (NASDAQ:TVTX) stock fell Tuesday as the company faces significant selling pressure following a corporate update that raised concerns among investors.

The stock’s decline comes as the broader market is experiencing mixed performance, with the S&P 500 down 0.16% and the Nasdaq slightly up by 0.02%.

FDA Review Update

On Tuesday, the U.S. Food and Drug Administration (FDA) extended the review timeline of Travere Therapeutics’ supplemental New Drug Application (sNDA) for Filspari (sparsentan) in focal segmental glomerulosclerosis (FSGS).

The new Prescription Drug User Fee Act (PDUFA) target action date is April 13.

The extension follows the recent submission of responses requested by the FDA to further characterize the clinical benefit of Filspari.

No additional information relating to the safety or manufacturing of Filspari has been requested.

In its preliminary financial results on Tuesday, the company said it received additional information requests from the FDA to further characterize the clinical benefit of Filspari and recently submitted responses.

If approved, Filspari would be the first medication indicated for FSGS, a rare and serious kidney disorder driven by proteinuria that leads to progressive kidney function loss and kidney failure.

Filspari is fully approved by the FDA and European Medicines Agency to slow kidney function decline in adults with IgA nephropathy.

TVTX Announces Q4 2025 Sales Forecast

On Monday, Travere announced that U.S. net product sales for the fourth quarter of 2025 are expected to be approximately $127 million.

The company also highlighted that it received a $40 million milestone payment from its collaborator, CSL Vifor, following market access achievements.

Travere on Monday said that following further optimization of its manufacturing process in 2025, it is on track to restart the pivotal Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria in the first quarter of 2026.

TVTX Stock Faces Bearish Technical Indicators

The stock is currently trading 35.8% below its 20-day simple moving average (SMA) and 21.2% below its 100-day SMA, indicating a bearish trend in the short to medium term. Over the past 12 months, shares have increased by 25.82%, and they are currently positioned closer to their 52-week lows than highs, reflecting the recent volatility.

The RSI is at 43.36, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum.

• Key Resistance: $26.00
• Key Support: $22.00

TVTX Analyst Ratings

The stock has an average price target of $36.31. Recent analyst moves include:

• HC Wainwright & Co.: Buy (Target $47.00)
• Piper Sandler: Neutral (Raised Target to $35.00)
• TD Cowen: Buy (Raised Target to $40.00)

TVTX Scores High on Benzinga Edge Momentum

Below is the Benzinga Edge scorecard for Travere Therapeutics, Inc. Common Stock (TVTX), highlighting its strengths and weaknesses compared to the broader market:

• Momentum: Bullish (Score: 94.7/100) — Stock is outperforming the broader market.

TVTX’s Impact on Key ETFs

• First Trust Small Cap Core AlphaDEX Fund (NASDAQ:FYX): 0.46% Weight
• First Trust Small Cap Growth AlphaDEX Fund (NASDAQ:FYC): 0.91% Weight
• F/m Emerald Life Sciences Innovation ETF (NASDAQ:LFSC): 5.04% Weight

TVTX Price Action: Travere Therapeutics shares were down 3.13% at $28.20 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo by Tada Images via Shutterstock